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Multiple myeloma (MM) is an incurable cancer of the plasma cell and currently only has
a 5 year survival rate of 53%. MM cells depend on a multitude of cells within the bone
maffow microenvironment to flourish and resist treatment-induced cell death. Bone
marrow adipocytes (BMAd), which increase in number with aging and obesity, have been
shown to support myeloma cells by inducing proliferation, migration, and drug
resistance, and ultimately contributing to myeloma patient relapse from remission. Herein
we confirm the pro-myeloma effects of BMAd conditioned media (CM) and investigate
the effects of the family of proteins termed the fatty acid binding proteins (FABPs),
which are expressed both by adipocytes and tumor cells themselves. We found that high
levels of FABP5 in patient myeloma cells corresponds to poor overall and relapse free
survival for MM patients. Moreover, we found that pharmacologically inhibiting fatty
acid binding proteins negatively impact tumor burden in vitro and in vivo,ultimately
leading to increased survival of tumor-bearing mice. In addition, when combined with
FABP inhibitors, dexamethasone, a common anti-myeloma treatment, has increased
efficacy in vitro.Overall, these data suggest that FABPs are a novel target in myeloma
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INTRODUCTION
Multiple myeloma (MM) has been characteized as a clonal expansion of malignant
plasma cells, and accounts for approximately 10% of hematological neoplasms
(Rajkumar,2020).In the United States, myeloma is the ninth most common cause of
cancer related deaths among females and fourteenth among males (Alexander et al.,
2007). Myeloma cells home to the bone marrow (BM), leading to aberrant growth and
destruction of the BM microenvironment, often resulting in painful osteolytic lesions
(Fairfield, Falank, Avery, & Reagan, 2016; Falank, Fairfield, Farrell, & Reagan, 2017;
Reagan & Rosen, 2015). It has been extensively demonstrated that the BM niche supports
myeloma migration, invasion, proliferation and drug resistance (Fairfield et al., 2016;
Reagan, Liaw, Rosen, & Ghobrial, 2015). Treatments for myeloma patients have greatly
improved within the past two decades improving the f,rve year survival rate to 53.9Yo
("Myeloma 
- Cancer Stat Facts," n.d.). In fact, modern therapies have led to 
>60Yo of
newly-diagnosed multiple myeloma (NDMM) patients achieving complete response (CR)
(Landgren & Iskander, 2011). While there has been an increase in therapies available to
myeloma patients, most patients relapse and succumb to the disease, demonstrating the
need to pursue more novel treatments for MM.
Obesity and aging are two major risk factors for development and progression of
myeloma. Incidence rates of developing MM increase after the age of 40, with 2.1
persons per 100,000 person-years for individuals under the age of65 and 30.1 persons
per 100,000 person-years after the age of 65 (Alexander et a1.,2007). Several studies
found positive associates between obesity or high BMI and MM (Marinac et aI,2019).
Interestingly, Bullwinkle and colleagues found that an increase in BMI of 5 kg/m
2
increases the risk of MM by l0%.It has also been shown that high BMI correlates with
poor response to treatment (Bullwinkle et a1.,2016; Z. Liu et a1.,2015). Both aging and
obesity have been shown to cause elevated amounts of adipose tissue within the BM
(Bornstein et a1.,2017; Hardaway, Herroon, Rajagurubandara, & Podgorski, 2014;
Veldhuis-Vlug & Rosen, 2018). In fact, normal healthy BM in adults consists of more
ihan 50o/o bone marrow adipose tissue (BMAT) and more thanT0Yo of the cavity in
elderly patients (Veldhuis-Vlug & Rosen,20lS). BM adipocytes (BMAd) have been
shown to be supportive of myeloma cell proliferation, aggression and drug resistance in
many recent publications, and suggests that targeting of BMAd would increase the
longevity of MM patients (Bullwinkl e et al., 2016; Fairfield et al., 2020; Z. Liu et al.,
20 | 5 ; Morri s et al., 2020 ; Trotter et al., 20 I 6).
The fatty acid bind protein (FABP) family is composed of small molecular weight, l4-I5
kDa, proteins that can bind to hydrophobic ligands to contribute to transportation and
storage of lipids or influence signaling pathways. There are 10 isoforms within the FABP
family, and these are expressed in specific tissues. Atypical expression of FABPs has also
been linked to cancer. FABP4 overexpression drives proliferation of acute myeloid
leukemia, prostate and breast cancer (Guaita-Esteruelas et a1.,2016; Herroon et al., 2013;
Shafat et a1.,2017). FABP5, epidermal FABP/mall, expression influences prostate
metastasis, clear cell renal cell carcinoma and indicates poor prognosis in breast cancer
(Carbonetti et al., 2019; R. Z. Liu etal.,207l; Lv et a1.,2019). FABP7, orbrain FABP,
has been linked to numerous neoplasms such as breast cancer, melanoma, glioblastoma,
and colon cancer (Ma et a1.,2018). There are many inhibitors that have been used in the
literature to target FABPs, however, two that are used the most are 8MS309403 (BMS)
3
and SBFI-26 (SBFI). BMS is typically used as an inhibitor against FABP4, while SBFI
has been studied more in the context of FABPS. Both of these inhibitors bind to the
binding pocket of FABPs and inhibit signaling and transportation of lipid cargo (Al-
Jameel eta1.,2017,2019; Huang etal.,2017; Laouirem etal.,2019; Lee et al.,20ll;
Mukherjee et a1.,2020). Many studies demonstrate that increased FABP expression in
tumor cells leads to poorer clinical outcomes.
FABPs are influential in a multitude of different facets in malignant cells, but have yet to
be studied in MM. In a recent publication, researchers demonstrated that FABP4 was
released from BMAd, taken up by AML cells, and resulted in an increase in tumor cell
proliferation and drug resistance (Shafat et a1.,2017). The pro-tumor role of FABPs is
also supported by a publication on prostate cancer and FABP4 signaling (Herroon et al.,
2013). We recently published that BMAd support myeloma cell drug resistance in
transwell co-culture, suggesting that factors coming from BMAd supported MM cell
dexamethasone drug response (Fairfield et a1,2020). We hypothesized that BMAd
secreted factors, especially FABPs, support myeloma cell dexamethasone resistance, and
that inhibiting FABPs would have a negative effect on MM growth. Herein we are the
first to have investigated the role of FABPs in MM cell signaling with commonly used
pharmacological inhibitors in vitro and in vivo.
MATERIALS AND METHODS
Cell Culture
Human myeloma cell lines GFP*/Luc*MM1S (MMlS), Luc*RPMI-8226 (ATCC,
Manassas, VA) and mCherry*/Luc*OPM2 (OPM2) were maintained in RPMI 1640
medium supplemented with l0% FBS (Atlanta Biologicals, Flowery Branch, GA) and lX
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Antibiotic-Antimycotic (100 U/ml penicillin, 100 pglml streptomycin,0.25 prg/ml
fungizone) (ThermoFisher Scientific, Grand Island, NY). MM1S and OPM2 cells were
generously provided by Dr. Irene Ghobrial (Dana-Farber Cancer Institute, Boston, MA).
Human mesenchymal stromal cells (hMSCs) were isolated from the BM from de-
identified normal patients through the Maine Medical Center (MMC) Biobank and
differentiated into mature adipocytes for 2l days with an adipogenic cocktail as
previously described (Fairfield et al., 2019). BM adipocyte-derived conditioned media
(BMAd CM) was generated by collecting media after 48 hours from BMAds grown in
basal myeloma media described above (RPMI 1640,10oÁ FBS, lX Antibiotic-
Antimycotic). BMAd CM was then used experimentally at a 50:50 ratio of basal
media:BMAd CM by applying this to tumor cells for 72 hours.
Materials and Reagents
Recombinant FABP4 and FABP5 were purchased from Caymen Chemical (Ann Arbor,
MI) and dissolved into phosphate-buffered saline. Dexamethasone (dex) was purchased
from VWR,8MS3094013 (BMS) was obtained from Caymen Chemical and SBFI-26
was from Aobious (Gloucester, MA). These drugs were dissolved in DMSO to create
stock solutions.In vitro, dexamethasone was used at 80 pM; BMS and SBFI were used at
50 pM either as single treatments or in combination. FABP4 protein level was
determined using a FABP4 ELISA from R&D systems (Minneapolis, MN).
In Vívo Experiments and Bioluminescent Imaging
Eighrweek-old female Scid-beige mice were inoculated with 5 million MMIS cells. One
cohort of mice (n:12) were administered 5 mg/kg BMS, 1 mg/kg SBFI, or the
combination of the two drugs injected three times a week intraperitoneally starting one
5
day after tumor cell inoculation. A second cohort of mice (n:8) were administered 1
mg/kg SBFI, I mg/kg dexamethasone, or the combination injected three times a week
intraperitoneally (i.p), starting one day after tumor cell inoculation. Mice were weighed
prior to injections and were weighed throughout the experiment. Two weeks post-
inoculation, tumor burden was assessed with bioluminescent imaging (BLI) biweekly as
previously published (Natoni et a1.,2020). In short, mice were injected with 150 mg/kg
i.p. filter-sterilized D-luciferin substrate (VivoGlo, Promega) and imaged after 15
minutes in an IVIS@ Lumina LT (Perkin Elmer, Inc.; Waltham, MA). Data were acquired
and analyzed using Livinglmage software 4.5 ). (PerkinElmer). BLI and mouse weight
data were graphed and analyzed only for days in which all mice remained in the
study to avoid artifacts due to mouse death. Mice were frequently monitored for
clinical signs of treatment-related side effects. "Survival endpoints" were mouse death or
euthanasia as required by IACUC (Body composition score depends on a single
observation of >30o/o body weight loss, 3 consecutive measurements of >25Yobody
weight loss, or impaired hind limb use). Survival differences were analyzed by Kaplan-
Meier methodology.
Cell Numbero Cell Cycle, and Apoptosis
MM cell number was measured by using BLI, Cell Titer Glo (Promega, Madison, WI), or
RealTime Glo (Promega) and measured on a GLOMAX microplate reader (Promega).
Cell cycle analysis was done by staining with DAPI (0.5 pglml).Ki67 expression was
measured using Alexa fluor 647 human Ki67 antibody (Biolegend, San Diego, CA).
Apoptosis was measured using Annexin V/APC and DAPI (Biolegend). All analyses
were analyzed using a MACSQuant (Miltenyi Biotec, Bergisch Gladbach, Germany)
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flow cytometer with a minimum of 10,000 events collected. The flow cytometric data
was analyzed using FlowJo_Vl0 (BD Life Sciences, Ashland, OR).Analysis pathway
was gating based on FSC vs SCC, doublet exclusion of SSC-H vs SSC-W for cell cycle,
and then gating based of APC vs DAPI for apoptosis, DAPI histogram for cell cycle, and
APC for Ki67.
Gene Expression Analyses
Basal gene expression levels of FABP family members were assessed in MMIS, OPM-2,
RPMI-8226 myeloma cell lines utilizing RNA-Seq with RNA isolation, library
preparation, sequencing, and analysis protocols as previously described (Fairfield et al.,
2020).The Chng dataset with FABP4 and FABP5 mRNA transcript data was analyzed
from accession number GEO:GSE6477 using excel and methods as previously described
(Fairfield et al., 2020).TheZhan et al. dataset (GSEI32604) (Zhanetal.,2006), Carrasco
et al. (Carrasco et a1.,2006) dataset (GEO:GSE4452), and Mulligan et al. (Mulligan et
a1.,2007) (GEO: GSE9782) datasets were analyzed using OncoMine (ThermoFisher)
and plotted and analyzed using Graphpad Prism version 6.0 or higher.
Statistical Analysis
Data were analyzedby using Prism6 version 6.0 or higher (GraphPad). Unpaired
Student's t tests or one-way or two-way analysis of variance, ANOVA, using Tukey's
correction were performed. Data are expressed as mean * standard error of the mean.
,.{.*t(p< 0.0001. *l *p<0.001; **p<0.01; *p<0.05.
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RESULTS
Bone marrow adipocytes support myeloma cell growth, influence cell cycle and
trigger dexamethasone resistance in MMIS and OPM2 cells.
Previous publications suggested that BMAds release FABPs to support other cancer cells,
such as acute myeloid leukemia, ovarian cancer, and prostate cancer (Herroon et al.,
2013; Mukherjee eta1.,2020; Shafat etal.,2017). Similarly, MM cells can benefit from
BMAd to grow and aid in drug resistance (Fairfield et a1.,2020; Z. Liu et al., 2015;
Trotter et a1.,2016). Thus, we investigated if BMAd conditioned media (BMAd CM)
would elicit drug resistance in MM cells and if this was through FABP signaling. In a
series of 72hour experiments, cellular responses were analyzed with cell cycle,
apoptosis, andKiíT expression. BMAd CM elicited a significant increase in OPM2 cell
number and a trend towards an increase in cell number in MMIS cells (Fig. 14, D).
Dexamethasone, a common anti-MM treatment, elicited a 50Yo reduction in cell number,
but in the presence of BMAd CM, this was reducedto lÙYo in MMIS and OPM2 (Fig.
lB-C, E-F). MMIS Ki67 positive cells were reduced by 30% after dexamethasone
treatment, but this was reducedto l0o/o after combination treatment with BMAd CM (Fig.
1G-H). In terms of cell cycle, dexamethasone triggered an increase in G0/Gl and a
decrease in S, but this was reversed in the presence of BMAd CM (Fig. lI). Overall,
BMAd CM elicited drug resistance in MM cells and rescued the negative effect of
dexamethasone on cell number.
We next investigated if BMAd CM contained FABP4. ELISA revealed that BMAd CM
contained more FABP4 and that there was very little released from MMIS cells (Suppl.
Fig. lA). Surprisingly, MMIS cells cultured in BMAd CM for 72 hours had significantly
increased levels of FABP4 (Suppl. Fig. lB). It has been noted in the literature that FABPs
can compensate for one another, so \ile interrogated if intemal FABP4 and FABP5
mRNA levels are influenced after exposure to BMAd CM. While FABP4 levels
significantly increased intemally in MMlS cells exposed to BMAd CM, supporting the
protein data, FABP5 mRNA levels were significantly decreased by BMAd CM (Suppl.
Fig. 1C-D). Interestingly, when FABP4 or FABP5 protein was added exogenously into
the cultures with and without serum, MMIS and OPM2 cells did not increase their cell
number (Suppl. Fig. 2A-D). Overall this suggests that exposure to BMAd CM may
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FABPS is highty expressed in multiple myeloma cell lines and corresponds to worse
clinical outcomes in patients.
To investigate which FABPs are highly expressed in MM, we analyzed our previously
published RNAseq data of three MM cells lines, OPM2, MMlS, and RPMI8226.We
found that FABP5 was the most highly expressed FABP (seen in red) among all three cell
lines with average expression levels of 114, 98 and 24 RPKM (Reads Per Kilobase of
transcript, per Million mapped reads) in the OPM2, MMIS, and RPMI8226 cells,
respectively. The second most highly expressed FABP (seen in green) was FABP6 (5.3
RPKM) in OPM2 and FABP4 in MM1S (1.8 RPKM) and RPMI8226 (1.9 RPKM)
(Suppl. Table. l) (Fairfield et al., 2020). Due to its high expression level, we analyzedthe
association of FABP5 with myeloma disease using independent microarray datasets from
OncoMine; several datasets demonstrated a link between FABP5 and poor outcomes.
Analysis of the Zhan et al. dataset indicated that patients with the highest levels of
FABPï in MM cells had significantly shorter overall survival than patients with lowest
FABPï expression (Zhan et a1.,2006). This was true when comparing all patients,
stratified as the top and bottom 100 (HR:l .322,p:0.0105) (Fig. 2A) or separated as high
(n:207) or low (n:207) FABPï expression (HR:1 .374,p:0.0105) (Fig. 2B). This result
was confirmed in the Mulligan dataset (Mulligan eta1.,2007) (HR:l.37, p:0.0058) and
Carrasco dataset (HR :1.917, p:0.0491) (Fig. 2C-D) (Canasco et a1.,2006).
Interestingly, when MM patients were classified into seven molecular subtypes based on
the known genetic lesions (CD1 or CD2 of cyclin D translocation; HY: hyperdiploid; LB:
low bone disease; MF or MS with activation of MAF, MAFB, or FGRF3/MMSET; PR:
proliferation), patients in PR subtype, which is a signature of high-risk disease with poor
t2
prognosis, had significantly higher expression of MM cell FABP5 than those in the four
more favorable subtypes (Zhan et a1.,2006) (Fig. 2E). Moreover, in the Chng dataset,
relapsed patients showed significantly increased expression of FABP5 compared to
newly-diagnosed patients (Chng eta1.,2007) (Fig. 2F). Immunofluorescent imaging
revealed that patient samples also expressed high levels of FABP5, as demonstrated by
the red staining (Fig. 2G). Additionally, immunofluorescent staining revealed that OPM2
cells express high levels of FABP5 as seen by the red staining (Fig. 2H). Overall, our
data strongly suggest that FABP5 is a novel, high-risk factor in MM and targeting the
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Figure 2. FABPS expression levels corresponds to worse clinical outcomes in
MM. A, B) Kaplan-Meier analysis of overall survival of myeloma patient groups in
Zhan et al dataset stratihed as top (n:100) or bottom (n:100) FABPï, or high (n:207)
and low (n:207) FABPï. C) Kaplan-Meier analysis of overall survival of high
(n:100) and low (n:100) FABPï expression in MM patient in Mulligan et al. dataset.
D) Kaplan-Meier analysis of relapse-free survival of high (n:20) and low (n:20)
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Continued Figure 2. FABPS expression levels correspond to worse clinical
outcomes in MM. E) Molecular subtypes of MM cells were analyzed for FABP5
expression and significance between all groups and the highly aggressive subtype
(PR, proliferation) was observed using a One-way ANOVA with Dunnett's multiple
comparison testing. F) Data is shown from Chng from newly-diagnosed (ND) (n:73)
and relapsed MM patients (n:28) as mean with95o/o confidence interval (CI), with
statistical analysis performed using a Mann Whitney test. G) Myeloma cells from a
patient stained with CD38 (green), FABP5 (red) and DAPI (blue). H) OPM2 cells
stained with FABP5 (red) and DAPI (blue). Controls show the cells stained with the







Fatty acid binding protein inhibition impairs MM cell growth and induces apoptosis
in myeloma cells in a dose-dependent manner.
Next, we investigated the impact of FABP inhibition in several human MM cell lines
using two well-known FABP inhibitors, 8MS309403 (BMS) and SBFI-26 (SBFD. These
inhibitors have been used to inhibit FABP 3,4,5, and7, in several other publications,
suggesting that these inhibitors could be targeting other FABPs within MM cells (Al-
Jameel etal.,2017; Huang etal:,2017; Laouirem etal.,2019). However, according to
RNAseq data from Fairfield et al. (Suppl. Table 1A), FABP3,4, and 7 are expressed at a
much lower level than FABP5. A72-hour dose curve of BMS and SBFI demonstrated a
decrease in RPMI8226,OPM2, and MMIS cell numbers in a dose-dependent manner.
Both RPM[8226 and OPM2 had little to no luciferase activity by 100 ¡rM, and 150 ¡^rM in
the MMIS (Fig. 3A-C). To determine if this effect was specific to MM cells, human
mesenchymal stem cells were exposed to similar doses, revealing no significant decrease
in total ATP activity, a surrogate marker for cell number, unless at the high dose of 150
¡rM (data not shown). Next, we investigated how the inhibitors reduced cell numbers over
time. BLI revealed that within 72 hours, the vehicle treated cells tripled in number, as
expected. Single treatment of either inhibitor significantly reduced cell number compared
to the control at the 72hour time point (6I%, BMS, and 57o/o, SBFI compared to the
vehicle). Interestingly, the combination treatment significantly stunted growth (I7%
decrease in growth compared to day 0 seeding density) (Fig. 3D). Next, we investigated
cell cycle and apoptosis using flow-based analysis to determine the influence of the
FABP inhibitors. As early as 24 hours, we saw an increase in G1/G0 with the single
inhibitors, with a significant increase with combination treatment. The increase in G1/G0
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persisted throughout the 72 hour time course. Additionally, we saw a significant decrease
inG2lMwith both single inhibitors and the greatest reduction with the combination (Fig.
3E), overall suggesting a negative impact on cell cycle progression. In terms of apoptosis,
we saw a significant effect of the combination as early as 24 hours and this persisted
throughout the duration of the time course.By 72 hours, SBFI and the combination had
significantly more apoptosis than the vehicle (Fig. 3F). These data suggest inhibition of






































































Figure 3. FABP inhibition with SBFI or BMS significantly impairs cell growtho
cell cycle and induced apoptosis in MM cell lines. A-C) RPM[8226, OPM2, and
MMIS cells respond to SBFI or BMS in a dose dependent manner within 72 hours.
D) MMIS cells have significantly reduced cell growth over 72 hours with 50 prM
BMS, 50 pM SBFI or combination treatment of both at 50 ¡rM doses.
0 808040
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Continued Figure 3. FABP inhibition with SBFI or BMS significantly impairs
cell growth, cell cycle and induced apoptosis in MM cell lines. E) Cell cycle and F)
apoptosis is negatively impacted with 50 pM BMS, 50 ¡rM SBFI or combination
treatment of both at 50 pM in MM1S cells over a72hour time course.
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BMS, SBFI or the combination significantly decrease tumor burden and improve
survival in a multiple myeloma xenograft mouse model.
To confirm our invitro ftndings of myeloma growth inhibition with FABP inhibitors, we
moved in vivoto treat MMlS inoculated in 8-week-old, female Scid-beige mice. One day
post-inoculation, treatment began with either BMS, SBFI or the combination three times
weekly, i.p (Fig. 4A). Either single treatment or the combination did not significantly
influence the weight of the mice compared to the vehicle (Fig. aB). To monitor tumor
progression, mice were subjected to bioluminescence imaging twice weekly. A
significant difference in tumor burden was detected as early as day 2l inthe BMS, SBFI
and combination groups compared to the control. This trend in decreased tumor burden
continued throughout the duration of the study for all treatment groups. At day 28, we
saw significantly less tumor burden in the BMS treatment compared to either the SBFI or
the combination, but this was not reflected in the survival of the mice (Fig 4C-E). In fact,
mice that received BMS, SBFI or the combination had significantly longer survival than
the vehicle mice, which highlights the great promise of targeting the FABPs as a potential
treatment. We did not observe any negative side effects or signs of sickness from the
FABP inhibitors in these mice. Overall, single or combination treatment with BMS and
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Figure 4. FABP inhibition with SBFI or BMS significantly reduces tumor burden
in the MMIS xenograft model. A, B) Mice treated with the 1 mg/kg SBFI, 5 mg/kg
BMS or combination treatment have no negative effect on weight. C, E)
Bioluminescent imaging revealed a decrease in tumor bearing mice treated with
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Continued Figure 4. FABP inhibition with SBFI or BMS significantly reduces
tumor burden in the MMIS xenograft model. C-E) Bioluminescent imaging
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Inhibition of fatty acid binding proteins increases the efficacy of dexamethasone in
vitro and reduces MM cell number in the presence of bone marro\ry adipocyte
condition media.
Since we observed concurrent dexamethasone resistance and FABP4 expression in MM
cells cultured in BMAd CM, and that inhibition of FABPs impacted MM cell growth, we
hypothesized that inhibiting FABPs would resensitize MM cells to dexamethasone in
BMAd CM conditions. In basal media, dexamethasone in combination with the single
inhibitors significantly reduced cell number compared to all single treatments (-20%
survival of the control). However, the greatest reduction to cell number was the
combination treatment of dexamethasone, BMS and SBFI, resulting itn -SYosurvival (Fig.
5A). In BMAd CM conditions, there was no reduction in cell number with
dexamethasone, reaffrrming resistance. Single inhibitors reduced MM cell numbers
compared to the BMAd CM control (BMS 33Yo, and SBFI 41%). In combination, BMS
and SBFI significantly reduced cell number compared to the BMAd CM control (BMS +
SBFI 12%) and the BMAd CM single inhibitor treatments (2lYo compared to BMS, and
29o/o compared to SBFI). Surprisingly in BMAd CM conditions, dexamethasone
combined with either single inhibitors or the combination of inhibitors did not resensitize
the MM cells to dexamethasone. Combination treatment of dexamethasone and BMS or
SBFI had similar luciferase activity to the single inhibitors. The triple treatment had the
same luciferase activity as the BMS and SBFI combination (Fig. 5B). Consistent with
these findings, dexamethasone induced a 3-fold increase in apoptosis in basal conditions,
but there was no increase in apoptosis with the single inhibitors (Fig. 5C).
Dexamethasone co-treatment with either inhibitor resulted in significant apoptosis
23
compared to the control or dexamethasone alone. The combination of both inhibitors did
not increase apoptosis; however, a combination of BMS, SBFI and dexamethasone
triggered a 7-fold increase in apoptosis compared to the control. Importantly, dual
inhibition with dexamethasone treatment significantly increased MM cell apoptosis
compared to dexamethasone alone, or the single inhibitors and dexamethasone (Fig. 5C).
In BMAd CM conditions, dexamethasone alone did not increase apoptosis relative to
control, nor did the single inhibitors. Interestingly, triple treatment induced signihcantly
more apoptosis compared to the control (1.8-fold), dexamethasone alone, BMS alone, or
BMS and dexamethasone combination. In comparison, there was no signiflrcance between
BMS alone, SBFI and dexamethasone, or BMS and SBFI (Fig. 5D, Suppl. Table 2).
While FABP inhibition did not reverse drug resistance, it still reduced cell number and
















































Figure 5. BMAd CM induced dexamethasone resistance in MMIS cells is not
reverse with FABP inhibition. A) MMlS cells treated with 80 ¡rM dex, 50 ¡rM
BMS, 50 ¡rM SBFI, or the combination reduces cell number. B) BMAd CM induced
dex resistance, but BMS and SBFI treatment reduces cell number. C) Dex, BMS,
SBFI or the combinations induce apoptosis after 72 hour treatment in MMIS cells. D)
BMAd CM induces dex resistance, but BMS, SBFI and the combinations induce
apoptosis after 72 hour treatment in MMlS cells.
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In vívo combination treatment of FABP inhibitor with dexamethasone does not
reduce tumor burden.
To test our final hypothesis that an FABP inhibitor would synergize with dexamethasone
invivo, we combined SBFI and dexamethasone in the Scid-beige MMIS mouse model.
The treatment schedule was that either the vehicle, 1 mg/kg SBFI, 1 mg/kg
dexamethasone, or the combination was administered i.p for the first three weeks of
treatment. After, seeing no combined effect with this low dose of dexamethasone, the
dexamethasone was increased to 9 mg/þ for the duration of the study (Fig. 6A). There
were no negative side effects of the SBFI or dexamethasone treatments on weight or
behavior of the mice (Suppl. Fig. 3A). BLI revealed that 1 mgirg dexamethasone did not
significantly reduce tumor burden within three weeks, but when dexamethasone was
increased to 9 mg/kg, tumor burden was significantly reduced (Fig. 6B-C). Interestingly,
the "SBFI only" group had a significant negative effect at day 23, which set a trend for
less tumor burden throughout the study (Suppl. Fig. 3B). Surprisingly, combination
treatment did not significantly reduce tumor burden compared to the vehicle, SBFI alone,
or dexamethasone alone. Overall, these data suggest that while dexamethasone and SBFI
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Figure 6. SBFI is as potent as a single agent compared to combination with
dexamethasone in MMIS xenograft study. A-B) MMIS xenograft mice treated
with I mg/kg SBFI, 1 -glkg and 9 mglkg dex, or the combination have various
responses with tumor burden.
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DISCUSSION
In this thesis, I describe a series of studies where we examined the relationship between
BMAd, myeloma cells and FABPs. We also studied how FABPs and BMAd can alter
myeloma cell growth, apoptosis, proliferation, and response to a commonly prescribed
chemotherapeutic agent, dexamethasone. We found that in MMIS and OPM2 cells, cell
numbers were increased in BMAd derived conditioned media. Additionally, MMlS cells
were resistant to dexamethasone in BMAd CM as shown by a rescue in their cell number,
a decrease in their apoptotic response, a rescue of their cell cycle progression, and
restoration of their Ki67 potential. BMAd release a high volume of FABP4, and exposure
to BMAd CM elicits an increase in internal FABP4 in MMIS cells, supporting recent
findings (Shu, 2020). Additionally, we observed that the fatty acid binding protein family
is important to MM cell growth using 3 cell lines that represent different type of MM
harboring different genetic abnormalities (RPMI8226, MMIS and OPM2 cell lines).
Basally, single inhibitors of FABP4 and 5 significantly impaired cell growth over time,
and this is consistent even in the presence of tumor-supportive BMAd CM. In addition,
when the single inhibitors were used in combination with dexamethasone, there was a
significant decrease in cell number and significantly increased apoptosis compared to
dexamethasone treatment alone in basal conditions. Importantly, combination treatment
of BMS, SBFI and dexamethasone resulted in the greatest reduction in cell number and
significantly higher apoptosis compared to any other treatment, resulting in an almost 7-
fold increase compared to the control in basal conditions. While FABP inhibition did not
reverse drug resistance in BMAd CM, combining the duel inhibitors resulted in a
significant increase in apoptosis and significant reduction in cell number. In summary,
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these data suggest that duel inhibition of BMS and SBFI does not resensitize MM cells to
dexamethasone in BMAd CM, and supports previous studies that additional adipokines
are likely involved in BMAd-induced drug resistance (H. Liu et a1.,2019;Z.Liu et al.,
2015). A need for future studies in myeloma dexamethasone drug resistance are needed
to elucidate other molecules in BMAd CM alleviating MM cells from dexamethasone-
induced apoptosis (M. L. Farrell & Reagan, 2018).
Overall, targeting the FABP family appears to be a promising new target in myeloma,
which could prove to be relevant in essentially all other forms of cancer. While targeting
FABPs does not reverse dexamethasone resistance, targeting FABP5 looks to be
clinically and translationally promising in multiple myeloma. FABP3, FABP4, FABP5,
and FABP6 are expressed in three common myeloma lines, with FABP5 being the
highest expressed. Clinically, high FABP5 expression correlates with poor outcomes and
is significantly higher in relapsed patients. Targeting the family of FABPs with the
pharmacological pan inhibitors, SBFI-26 and 8MS309403, impaired myeloma growth
and induced a level of apoptosis in vitro.Inhibition of FABPs in vivo significantly
reduced tumor burden and extended the life span of mice. While our dexamethasone-
SBFI in vivo experiment did not demonstrate synergy, it is possible that higher doses than
we used herein could have better effects. Our data suggest that targeting FABPs could be
a beneficial and important avenue to treat myeloma or other cancer patients (M. Farrell,
Fairf,reld, D'Amico, Murphy, & Reagan, 2020).
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In future studies, we plan to broaden the scope of combination treatments to extend to
other anti-myeloma therapies both in terms of drug resistance and combination of FABP
inhibitors. We would plan to interrogate the in vitro effects of BMAds and FABPs on
MM resistance to proteasome inhibitors and/or immunomodulatory imide drugs, and
determine the mechanisms driving this type of resistance. In vivo, we plan to use mouse
models that have high BMAT either due to irradiation or diet, and test if MM cells are
resistant to other agents beyond dexamethasone. This year, I also published as first author
a manuscript showing that BM adiposity is reduced with anti-sclerostin antibody
treatment, suggesting that anti-sclerostin antibody could be used in combination with
dexamethasone to elucidate if MM cells respond better to dexamethasone when the
microenvironment is depleted of BMAd (M. Fanell, Fairfield, Costa, eta1.,2020).We
are also interested in using a commonly used antibiotic, Levofloxacin, to treat myeloma
burdened mice to reduce tumor growth. Levofloxacin has been showed to inhibit FABP4
activity and is currently used in the clinic for treatments in other cancers (Mukherjee et
a1.,2020).
Myeloma is currently incurable and the median survival is only five years, highlighting
that novel new treatments are needed to expand the quality and duration of life. Our data
illuminate that FABP5 is a novel therapeutic target and our findings demand more
investigation into its role in myeloma due to its potential of curing, or increasing life
expectancy for patients with this deadly disease.
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Supplemental Figure 1. FABP gene and protein expression levels are
influenced by BMAd CM. A, B) FABP4 protein levels are higher in BMAd CM
and in MM after BMAd CM treatment, as determined by ELISA. C) MM1S mRNA



























































Supplemental Figure 2. Exogenously added recombinant FABP4 or 5 protein
does not influence cell number. A, B) Exogenously added recombinant FABP4 or 5
protein did not influence MMlS cell number. C, D) Exogenously added recombinant






























Supplemental Table 1. FABPS is the highest expressed FABP in OPM2'
RPMI8226 and MMIS cells. A) Basal expression levels of FABPs in OPM2,
RPMI8226 and MM1S cells determined by RNAseq.
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Supplemental Table 2. Combinatorial treatment of dexamethasone, BMS and
SBFI induce apoptosis and reduce cell number after 72 hour treatment in MMIS
cells. A-D) Statistical importance of treatment with 50 pM BMS, 50 pM SBFI, 80 pM
dex and the combinations after 12 hours in MMIS cells.
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Supplemental Figure 4. SBFI, dexamethasone, or the combination treated mice
maintain weight. A) No weight difference between treatment groups over the
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ABSTRACT
Multiple myeloma (MM) is an incurable cancer of the plasma cell and currently only has
a 5 year survival rate of 53%. MM cells depend on a multitude of cells within the bone
marrow microenvironment to flourish and resist treatment-induced cell death. Bone
maffow adipocytes (BMAd), which increase in number with aging and obesity, have been
shown to support myeloma cells by inducing proliferation, migration, and drug
resistance, and ultimately contributing to myeloma patient relapse from remission. Herein
we confirm the pro-myeloma effects of BMAd conditioned media (CM) and investigate
the effects of the family of proteins termed the fatty acid binding proteins (FABPs),
which are expressed both by adipocytes and tumor cells themselves. We found that high
levels of FABP5 in patient myeloma cells corresponds to poor overall and relapse free
survival for MM patients. Moreover, we found that pharmacologically inhibiting fatty
acid binding proteins negatively impact tumor burden in vitro and in vivo, ultimately
leading to increased survival of tumor-bearing mice. In addition, when combined with
FABP inhibitors, dexamethasone, a common anti-myeloma treatment, has increased
efficacy in vitro. Overall, these data suggest that FABPs are a novel target in myeloma
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INTRODUCTION
Multiple myeloma (MM) has been characterized as a clonal expansion of malignant
plasma cells, and accounts for approximately l0% of hematological neoplasms
(Rajkumar, 2020).In the United States, myeloma is the ninth most common cause of
cancer related deaths among females and fourteenth among males (Alexander et al.,
2001). Myeloma cells home to the bone marrow (BM), leading to aberrant growth and
destruction of the BM microenvironment, often resulting in painful osteolytic lesions
(Fairheld, Falank, Avery, & Reagan, 2016; Falank, Fairfield, Farrell, & Reagan, 2017;
Reagan & Rosen, 2015).It has been extensively demonstrated that the BM niche supports
myeloma migration, invasion, proliferation and drug resistance (Fairfield et al., 2016;
Reagan, Liaw, Rosen, & Ghobrial, 2015). Treatments for myeloma patients have greatly
improved within the past two decades improving the five year survival rate to 53.9%:o
("Myeloma 
- Cancer Stat Facts," n.d.). In fact, modern therapies have led to 
>600/o of
newly-diagnosed multiple myeloma (NDMM) patients achieving complete response (CR)
(Landgren & Iskander,2017). While there has been an increase in therapies available to
myeloma patients, most patients relapse and succumb to the disease, demonstrating the
need to pursue more novel treatments for MM.
Obesity and aging are two major risk factors for development and progression of
myeloma. Incidence rates of developing MM increase after the age of 40, with 2.1
persons per 100,000 person-years for individuals under the age of65 and 30.1 persons
per 100,000 person-years after the age of 65 (Alexander et a1.,2007). Several studies
found positive associates between obesity or high BMI and MM (Marinac et a1.,2019).
Interestingly, Bullwinkle and colleagues found that an increase in BMI of 5 kg/m
2
increases the risk of MM by l0%.It has also been shown that high BMI correlates with
poor response to treatment (Bullwinkle et a1.,2016; Z. Liu et a1.,2015). Both aging and
obesity have been shown to cause elevated amounts of adipose tissue within the BM
(Bomstein et al., 2017; Hardaway, Herroon, Rajagurubandara, &, Podgorski, 2014
Veldhuis-Vlug & Rosen, 2018). In fact, normal healthy BM in adults consists of more
than 50Yo bone marrow adipose tissue (BMAT) and more thanT0Yo of the cavity in
elderly patients (Veldhuis-Vlug & Rosen, 20lS). BM adipocytes (BMAd) have been
shown to be supportive of myeloma cell proliferation, aggression and drug resistance in
many recent publications, and suggests that targeting of BMAd would increase the
longevity of MM patients (Bullwinkle et al., 2016; Fairfield eta1.,2020;Z.Liluetal.,
2015; Morris et a1.,2020; Trotter et a1.,2016).
The fatty acid bind protein (FABP) family is composed of small molecular weight, 14-15
kDa, proteins that can bind to hydrophobic ligands to contribute to transportation and
storage of lipids or influence signaling pathways. There are l0 isoforms within the FABP
family, and these are expressed in specif,rc tissues. Atypical expression of FABPs has also
been linked to cancer. FABP4 overexpression drives proliferation of acute myeloid
leukemia, prostate and breast cancer (Guaita-Esteruelas et a1.,2016; Herroon et al.,2013;
Shafat et al., 2017). FABPS, epidermal FABP/mal1, expression influences prostate
metastasis, clear cell renal cell carcinoma and indicates poor prognosis in breast cancer
(Carbonetti et al., 2019; R. Z. Liu et al,20ll; Lv et al., 2019). FABP7, or brain FABP,
has been linked to numerous neoplasms such as breast cancer, melanoma, glioblastoma,
and colon cancer (Ma et al., 2018). There are many inhibitors that have been used in the
literature to target FABPs, however, two that are used the most are 8MS309403 (BMS)
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and SBFI-26 (SBFÐ. BMS is typically used as an inhibitor against FABP4, while SBFI
has been studied more in the context of FABP5. Both of these inhibitors bind to the
binding pocket of FABPs and inhibit signaling and transportation of lipid cargo (Al-
Jameel et al., 2017,2019; Huang et a1.,2017; Laouirem et a1.,2019; Lee et al.,20Il;
Mukherjee et a1.,2020). Many studies demonstrate that increased FABP expression in
tumor cells leads to poorer clinical outcomes.
FABPs are influential in a multitude of different facets in malignant cells, but have yet to
be studied in MM. In a recent publication, researchers demonstrated that FABP4 was
released from BMAd, taken up by AML cells, and resulted in an increase in tumor cell
proliferation and drug resistance (Shafat et a1., 2017). The pro-tumor role of FABPs is
also supported by a publication on prostate cancer and FABP4 signaling (Herroon et al.,
2013). We recently published that BMAd support myeloma cell drug resistance in
transwell co-culture, suggesting that factors coming from BMAd supported MM cell
dexamethasone drug response (Fairfield et a1.,2020). We hypothesized that BMAd
secreted factors, especially FABPs, support myeloma cell dexamethasone resistance, and
that inhibiting FABPs would have a negative effect on MM growth. Herein we are the
first to have investigated the role of FABPs in MM cell signaling with commonly used
pharmacological inhibitors in vitro and in vivo.
MATERIALS AND METHODS
Cell Culture
Human myeloma cell lines GFP*/Luc*MMIS (MMIS), Luc*RPMI-8226 (ATCC,
Manassas, VA) and mCherry*/Luc*OPM2 (OPM2) were maintained in RPMI 1640
medium supplemented with 10% FBS (Atlanta Biologicals, Flowery Branch, GA) and lX
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Antibiotic-Antimycotic (100 U/ml penicillin, 100 ¡tglml streptomycin,0.25 ¡rglml
fungizone) (ThermoFisher Scientific, Grand Island, NY). MMIS and OPM2 cells were
generously provided by Dr. Irene Ghobrial (Dana-Farber Cancer Institute, Boston, MA).
Human mesenchymal stromal cells (hMSCs) were isolated from the BM from de-
identified normal patients through the Maine Medical Center (MMC) Biobank and
differentiated into mature adipocytes for 2I days with an adipogenic cocktail as
previously described (Fairfield et a1.,2019). BM adipocyte-derived conditioned media
(BMAd CM) was generated by collecting media after 48 hours from BMAds grown in
basal myeloma media described above (RPMI 1640,l0yo FBS, lX Antibiotic-
Antimycotic). BMAd CM was then used experimentally at a 50:50 ratio of basal
media:BMAd CM by applying this to tumor cells for 72 hours.
Materials and Reagents
Recombinant FABP4 and FABP5 were purchased from Caymen Chemical (Ann Arbor,
MI) and dissolved into phosphate-buffered saline. Dexamethasone (dex) was purchased
from VWR, 8MS3094013 (BMS) was obtained from Caymen Chemical and SBFI-26
was from Aobious (Gloucester, MA). These drugs were dissolved in DMSO to create
stock solutions. In vitro, dexamethasone was used at 80 pM; BMS and SBFI were used at
50 pM either as single treatments or in combination. FABP4 protein level was
determined using a FABP4 ELISA from R&D systems (Minneapolis, MN).
In Vìvo Experiments and Bioluminescent Imaging
Eight-week-old female Scid-beige mice were inoculated with 5 million MMIS cells. One
cohort of mice (n:12) were administered 5 mglkg BMS, I mglkg SBFI, or the
combination of the two drugs injected three times a week intraperitoneally starting one
5
day after tumor cell inoculation. A second cohort of mice (n:8) were administered I
mglkg SBFI, 1 mg/kg dexamethasone, or the combination injected three times a week
intraperitoneally (i.p), starting one day after tumor cell inoculation. Mice were weighed
prior to injections and were weighed throughout the experiment. Two weeks post-
inoculation, tumor burden was assessed with bioluminescent imaging (BLI) biweekly as
previously published (Natoni et a1.,2020).In short, mice were injected with 150 mg/kg
i.p. filter-sterilized D-luciferin substrate (VivoGlo, Promega) and imaged after l5
minutes in an IVIS@ Lumina LT (Perkin Elmer, Inc.; Waltham, MA). Data were acquired
and analyzed using Livinglmage software 4.5.1. (PerkinElmer). BLI and mouse weight
data were graphed and analyzed only for days in which all mice remained in the
study to avoid artifacts due to mouse death. Mice were frequently monitored for
clinical signs of treatment-related side effects. "Survival endpoints" were mouse death or
euthanasia as required by IACUC (Body composition score depends on a single
observation of >30%o body weight loss, 3 consecutive measurements of >25o/obody
weight loss, or impaired hind limb use). Survival differences were analyzedby Kaplan-
Meier methodology.
Cell Number, Cell Cycle, and Apoptosis
MM cell number was measured by using BLI, Cell Titer Glo (Promega, Madison, WI), or
RealTime Glo (Promega) and measured on a GLOMAX microplate reader (Promega).
Cell cycle analysis was done by staining with DAPI (0.5 pg/ml).Ki67 expression was
measured using Alexa fTuor 647 human Ki67 antibody (Biolegend, San Diego, CA).
Apoptosis was measured using Annexin V/APC and DAPI (Biolegend). All analyses
were analyzed using a MACSQuant (Miltenyi Biotec, Bergisch Gladbach, Germany)
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flow cytometer with a minimum of 10,000 events collected. The flow cytometric data
was analyzed using FlowJo_Vl0 (BD Life Sciences, Ashland, OR).Analysis pathway
was gating based on FSC vs SCC, doublet exclusion of SSC-H vs SSC-W for cell cycle,
and then gating based of APC vs DAPI for apoptosis, DAPI histogram for cell cycle, and
APC for Ki67.
Gene Expression Analyses
Basal gene expression levels of FABP family members were assessed in MMlS, OPM-2,
RPMI-8226 myeloma cell lines utilizing RNA-Seq with RNA isolation, library
preparation, sequencing, and analysis protocols as previously described (Fairfield et al.,
2020).The Chng dataset with FABP4 and FABP5 mRNA transcript data was analyzed
from accession number GEO:GSE6477 using excel and methods as previously described
(Fairfield eta1.,2020).TheZhan et al. dataset (GS8132604) (Zhanetal.,2006), Carrasco
et al. (Canasco et a1.,2006) dataset (GEO:GSE4452), and Mulligan etal. (Mulligan et
a1.,2007) (GEO: GSE9782) datasets were analyzed using OncoMine (ThermoFisher)
and plotted and analyzed using Graphpad Prism version 6.0 or higher.
Statistical Analysis
Data were analyzed by using Prism6 version 6.0 or higher (GraphPad). Unpaired
Student's t tests or one-way or two-way analysis of variance, ANOVA, using Tukey's
correction were performed. Data are expressed as mean t standard error of the mean.
****p( 0.0001. *r,*p<0.001; **p<0.01; *p<0.05.
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RESULTS
Bone marrow adipocytes support myeloma cell growth, influence cell cycle and
trigger dexamethasone resistance in MMIS and OPM2 cells.
Previous publications suggested that BMAds release FABPs to support other cancer cells,
such as acute myeloid leukemia, ovarian cancer, and prostate cancer (Herroon et al.,
2013; Mukherjee et a1.,2020; Shafat et a1.,2017). Similarly, MM cells can benefit from
BMAd to grow and aid in drug resistance (Fairfield et a1,2020; Z. Liu et a1.,2015;
Trotter etal.,2016). Thus, we investigated if BMAd conditioned media (BMAd CM)
would elicit drug resistance in MM cells and if this was through FABP signaling. In a
series of 72hour experiments, cellular responses were analyzed with cell cycle,
apoptosis, andKiíT expression. BMAd CM elicited a significant increase in OPM2 cell
number and a trend towards an increase in cell number in MMlS cells (Fig. 14, D).
Dexamethasone, a common anti-MM treatment, elicited a 50Yo reduction in cell number,
but in the presence of BMAd CM, this was reducedto llYo in MMIS and OPM2 (Fig.
lB-C, E-F). MMIS Ki67 positive cells were reduced by 30% after dexamethasone
treatment, but this was reducedto l0o/o after combination treatment with BMAd CM (Fig.
1G-H). In terms of cell cycle, dexamethasone triggered an increase in GO/G1 and a
decrease in S, but this was reversed in the presence of BMAd CM (Fig. 1I). Overall,
BMAd CM elicited drug resistance in MM cells and rescued the negative effect of
dexamethasone on cell number.
We next investigated if BMAd CM contained FABP4. ELISA revealed that BMAd CM
contained more FABP4 andthat there was very little released from MM1S cells (Suppl.
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Fig. 1A). Surprisingly, MMlS cells cultured in BMAd CM for 72 hours had significantly
increased levels of FABP4 (Suppl. Fig. 1B). It has been noted in the literature that FABPs
can compensate for one another, so we interrogated if intemal FABP4 and FABP5
mRNA levels are influenced after exposure to BMAd CM. While FABP4 levels
significantly increased internally in MMlS cells exposed to BMAd CM, supporting the
protein data, FABP5 mRNA levels were significantly decreased by BMAd CM (Suppl.
Fig. 1C-D). Interestingly, when FABP4 or FABP5 protein was added exogenously into
the cultures with and without serum, MMIS and OPM2 cells did not increase their cell
number (Suppl. Fig. 2A-D). Overall this suggests that exposure to BMAd CM may

































































=*F1äi3;EúÞsl='8.<F =E g *Ë ÈP.:i2.3Ës3: qiËÊ
'ü-.d".?S
9;=?UÈ* å r 3ã 3'à ñ õ' ä 
= 
B
Ë iË ã f gá +5 S - õtågg-rng8



































Kl67o/o Positive Cell s Y


































FABPS is highly expressed in multiple myeloma cell lines and corresponds to worse
clinical outcomes in patients.
To investigate which FABPs are highly expressed in MM, we analyzed our previously
published RNAseq data of three MM cells lines, OPM2, MMlS, and RPMI8226.We
found that FABP5 was the most highly expressed FABP (seen in red) among all three cell
lines with average expression levels of 114,98 and 24 RPKM (Reads Per Kilobase of
transcript, per Million mapped reads) in the OPM2, MMIS, and RPMI8226 cells,
respectively. The second most highly expressed FABP (seen in green) was FABP6 (5.3
RPKM) in OPM2 and FABP4 in MMIS (1.8 RPKM) and RPMI8226 (1.9 RPKM)
(Suppl. Table. 1) (Fairfield et a1.,2020). Due to its high expression level, we analyzedthe
association of FABP5 with myeloma disease using independent microarray datasets from
OncoMine; several datasets demonstrated a link between FABP5 and poor outcomes.
Analysis of the Zhan et al. dataset indicated that patients with the highest levels of
FABP5 in MM cells had significantly shorter overall survival than patients with lowest
FABPï expression (Zhan et a1.,2006). This was true when comparing all patients,
stratified as the top and bottom 100 (HR:1 .322,p:0.0105) (Fig. 2A) or separated as high
(n:207) or low (n:207) FABP5 expression (HR:l.374, p:0.0105) (Fig. 2B). This result
was confirmed in the Mulligan dataset (Mulligan eta1.,2007) (HR:I.37, p:0.0058) and
Carrasco dataset (HR:1.917, p:0.0491) (Fig. 2C-D) (Carrasco eta1.,2006).
Interestingly, when MM patients were classified into seven molecular subtypes based on
the known genetic lesions (CDl or CD2 of cyclin D translocation; HY: hyperdiploid; LB:
low bone disease; MF or MS with activation of MAF, MAFB, or FGRF3/MMSET; PR:
proliferation), patients in PR subtype, which is a signature of high-risk disease with poor
t2
prognosis, had significantly higher expression of MM cell FABPS than those in the four
more favorable subtypes (Zhan et a1.,2006) (Fig. 2E). Moreover, in the Chng dataset,
relapsed patients showed significantly increased expression of FABP5 compared to
newly-diagnosed patients (Chng et a1.,2007) (Fig. 2F). Immunofluorescent imaging
revealed that patient samples also expressed high levels of FABP5, as demonstrated by
the red staining (Fig. 2G). Additionally, immunofluorescent staining revealed that OPM2
cells express high levels of FABP5 as seen by the red staining (Fig. 2H). Overall, our
data strongly suggest that FABP5 is a novel, high-risk factor in MM and targeting the
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Figure 2. FABPS expression levels corresponds to worse clinical outcomes in
MM. A, B) Kaplan-Meier analysis of overall survival of myelomapatient groups in
Zhan et al dataset stratified as top (n:100) or bottom (n:100) FABPï, or high (n:207)
and low (n:207) FABPï. C) Kaplan-Meier analysis of overall survival of high
(n:100) and low (n:100) FABPS expression in MM patient in Mulligan et al. dataset.
D) Kaplan-Meier analysis of relapse-free survival of high (n:20) and low (n:20)




































Continued Figure 2. FABP5 expression levels correspond to worse clinical
outcomes in MM. E) Molecular subtypes of MM cells were analyzed for FABP5
expression and significance between all groups and the highly aggressive subtype
(PR, proliferation) was observed using a One-way ANOVA with Dunnett's multiple
comparison testing. F) Data is shown from Chng from newly-diagnosed (ND) (n:73)
and relapsed MM patients (n:28) as mean withgso/o confidence interval (CI), with
statistical analysis performed using a Mann Whitney test. G) Myeloma cells from a
patient stained with CD38 (green), FABP5 (red) and DAPI (blue). H) OPM2 cells
stained with FABP5 (red) and DAPI (blue). Controls show the cells stained with the






Fatty acid binding protein inhibition impairs MM cell growth and induces apoptosis
in myeloma cells in a dose-dependent manner.
Next, we investigated the impact of FABP inhibition in several human MM cell lines
using two well-known FABP inhibitors, 8MS309403 (BMS) and SBFI-26 (SBFD. These
inhibitors have been used to inhibit FABP 3, 4, 5, and 7 , in several other publications,
suggesting that these inhibitors could be targeting other FABPs within MM cells (Al-
Jameel et a1.,2017; Huang et a1.,2017; Laouirem et a1.,2019). However, according to
RNAseq data from Fairfield et al. (Suppl. Table 1A), FABP3,4, andT are expressed at a
much lower level than FABP5. A72-hour dose curve of BMS and SBFI demonstrated a
decrease in RPMI8226,OPM2, and MM1S cell numbers in a dose-dependent manner.
Both RPM[8226 and OPM2 had little to no luciferase activity by 100 pM, and 150 pM in
the MMIS (Fig. 3A-C). To determine if this effect was specific to MM cells, human
mesenchymal stem cells were exposed to similar doses, revealing no significant decrease
in total ATP activity, a surrogate marker for cell number, unless at the high dose of 150
¡rM (data not shown). Next, we investigated how the inhibitors reduced cell numbers over
time. BLI revealed that within 72 hours, the vehicle treated cells tripled in number, as
expected. Single treatment of either inhibitor significantly reduced cell number compared
to the control at the 7}hour time point (610/0, BMS, and 57o/o, SBFI compared to the
vehicle). Interestingly, the combination treatment significantly stunted growfh (17%
decrease in growth compared to day 0 seeding density) (Fig. 3D). Next, we investigated
cell cycle and apoptosis using flow-based analysis to determine the influence of the
FABP inhibitors. As early as 24 hours, we saw an increase in G1/G0 with the single
inhibitors, with a significant increase with combination treatment. The increase in G1iG0
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persisted throughout the 72 hour time course. Additionally, we saw a significant decrease
inG2lM with both single inhibitors and the greatest reduction with the combination (Fig.
3E), overall suggesting a negative impact on cell cycle progression. In terms of apoptosis,
we saw a significant effect of the combination as early as 24 hours and this persisted
throughout the duration of the time course.By 72 hours, SBFI and the combination had
significantly more apoptosis than the vehicle (Fig. 3F). These data suggest inhibition of

































































Figure 3. FABP inhibition with SBFI or BMS significantly impairs cell growth,
cell cycle and induced apoptosis in MM cell lines. A-C) RPMI8226, OPM2, and
MMIS cells respond to SBFI or BMS in a dose dependent manner within 72 hours.
D) MM1S cells have significantly reduced cell growth over 72 hours with 50 pM
BMS, 50 pM SBFI or combination treatment of both at 50 ¡rM doses.
t060/10


















































Continued Figure 3. FABP inhibition with SBFI or BMS significantly impairs
cell growth, cell cycle and induced apoptosis in MM cell lines. E) Cell cycle and F)
apoptosis is negatively impacted with 50 pM BMS, 50 pM SBFI or combination
treatment of both at 50 ¡rM in MM1S cells over aT2hotr time course.
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BMS, SBFI or the combination significantly decrease tumor burden and improve
survival in a multiple myeloma xenograft mouse model.
To confirm our in vitro findings of myeloma growth inhibition with FABP inhibitors, we
moved in vivo to treat MMlS inoculated in 8-week-old, female Scid-beige mice. One day
post-inoculation, treatment began with either BMS, SBFI or the combination three times
weekly, i.p (Fig. 4A). Either single treatment or the combination did not significantly
influence the weight of the mice compared to the vehicle (Fig. aB). To monitor tumor
progression, mice were subjected to bioluminescence imaging twice weekly. A
significant difference in tumor burden was detected as early as day 21 in the BMS, SBFI
and combination groups compared to the control. This trend in decreased tumor burden
continued throughout the duration of the study for all treatment groups. At day 28, we
saw significantly less tumor burden in the BMS treatment compared to either the SBFI or
the combination, but this was not reflected in the survival of the mice (Fig 4C-E). In fact,
mice that received BMS, SBFI or the combination had significantly longer survival than
the vehicle mice, which highlights the great promise of targeting the FABPs as a potential
treatment. We did not observe any negative side effects or signs of sickness from the
FABP inhibitors in these mice. Overall, single or combination treatment with BMS and


























Figure 4. FABP inhibition with SBFI or BMS significantly reduces tumor burden
in the MM1S xenograft model. A, B) Mice treated with the I mg/þ SBFI, 5 mg/kg
BMS or combination treatment have no negative effect on weight. C, E)
Bioluminescent imaging revealed a decrease in tumor bearing mice treated with




























Continued Figure 4. FABP inhibition with SBFI or BMS significantly reduces
tumor burden in the MM1S xenograft model. C-E) Bioluminescent imaging
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Inhibition of fatty acid binding proteins increases the efficacy of dexamethasone iz
vítro and reduces MM cell number in the presence of bone marrow adipocyte
condition media.
Since we observed concurrent dexamethasone resistance and FABP4 expression in MM
cells cultured in BMAd CM, and that inhibition of FABPs impacted MM cell growth, we
hypothesized that inhibiting FABPs would resensitize MM cells to dexamethasone in
BMAd CM conditions. In basal media, dexamethasone in combination with the single
inhibitors significantly reduced cell number compared to all single treatments (-20%
survival of the control). However, the greatest reduction to cell number was the
combination treatment of dexamethasone, BMS and SBFI, resulting in -5Yo survival (Fig.
5A). In BMAd CM conditions, there was no reduction in cell number with
dexamethasone, reaffirming resistance. Single inhibitors reduced MM cell numbers
compared to the BMAd CM control (BMS 33Yo, and SBFI41%). In combination, BMS
and SBFI significantly reduced cell number compared to the BMAd CM control (BMS +
SBFI 12%) and the BMAd CM single inhibitor treatments (2IYo compared to BMS, and
29o/o compared to SBFI). Surprisingly in BMAd CM conditions, dexamethasone
combined with either single inhibitors or the combination of inhibitors did not resensitize
the MM cells to dexamethasone. Combination treatment of dexamethasone and BMS or
SBFI had similar luciferase activity to the single inhibitors. The triple treatment had the
same luciferase activity as the BMS and SBFI combination (Fig. 5B). Consistent with
these findings, dexamethasone induced a 3-fold increase in apoptosis in basal conditions,
but there was no increase in apoptosis with the single inhibitors (Fig. 5C).
Dexamethasone co-treatment with either inhibitor resulted in significant apoptosis
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compared to the control or dexamethasone alone. The combination of both inhibitors did
not increase apoptosis; however, a combination of BMS, SBFI and dexamethasone
triggered a 7-fold increase in apoptosis compared to the control. Importantly, dual
inhibition with dexamethasone treatment significantly increased MM cell apoptosis
compared to dexamethasone alone, or the single inhibitors and dexamethasone (Fig. 5C).
In BMAd CM conditions, dexamethasone alone did not increase apoptosis relative to
control, nor did the single inhibitors. Interestingly, triple treatment induced significantly
more apoptosis compared to the control (1.8-fold), dexamethasone alone, BMS alone, or
BMS and dexamethasone combination. In comparison, there was no significance between
BMS alone, SBFI and dexamethasone, or BMS and SBFI (Fig. 5D, Suppl. Table2).
While FABP inhibition did not reverse drug resistance, it still reduced cell number and


















































Figure 5. BMAd CM induced dexamethasone resistance in MMIS cells is not
reverse with FABP inhibition. A) MMlS cells treated with 80 ¡rM dex, 50 pM
BMS, 50 ¡rM SBFI, or the combination reduces cell number. B) BMAd CM induced
dex resistance, but BMS and SBFI treatment reduces cell number. C) Dex, BMS,
SBFI or the combinations induce apoptosis after 72 hour treatment in MMlS cells. D)
BMAd CM induces dex resistance, but BMS, SBFI and the combinations induce
apoptosis after 72 hour treatment in MMIS cells.
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In vivo combination treatment of FABP inhibitor with dexamethasone does not
reduce tumor burden.
To test our final hypothesis that an FABP inhibitor would synergize with dexamethasone
ínvivo,we combined SBFI and dexamethasone in the Scid-beige MMIS mouse model.
The treatment schedule was that either the vehicle, I mg/kg SBFI, I mg/kg
dexamethasone, or the combination was administered i.p for the first three weeks of
treatment. After, seeing no combined effect with this low dose of dexamethasone, the
dexamethasone was increased to 9 mg/kg for the duration of the study (Fig. 6A). There
were no negative side effects of the SBFI or dexamethasone treatments on weight or
behavior of the mice (Suppl. Fig. 3A). BLI revealed that 1 mgkg dexamethasone did not
significantly reduce tumor burden within three weeks, but when dexamethasone was
increased to 9 mg/kg, tumor burden was significantly reduced (Fig. 6B-C). Interestingly,
the "SBFI only" group had a significant negative effect at day 23, which set a trend for
less tumor burden throughout the study (Suppl. Fig. 3B). Surprisingly, combination
treatment did not significantly reduce tumor burden compared to the vehicle, SBFI alone,
or dexamethasone alone. Overall, these data suggest that while dexamethasone and SBFI
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Figure 6. SBFI is as potent as a single agent compared to combination with
dexamethasone in MMIS xenograft study. A-B) MMlS xenograft mice treated
with 1 mglkg SBFI, I mg/kg and 9 mg/kg dex, or the combination have various
responses with tumor burden.
Day2o I loayzl I loayzz I Day 3O
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DISCUSSION
In this thesis, I describe a series of studies where we examined the relationship between
BMAd, myeloma cells and FABPs. We also studied how FABPs and BMAd can alter
myeloma cell growth, apoptosis, proliferation, and response to a commonly prescribed
chemotherapeutic agent, dexamethasone. We found that in MMlS and OPM2 cells, cell
numbers were increased in BMAd derived conditioned media. Additionally, MMIS cells
were resistant to dexamethasone in BMAd CM as shown by a rescue in their cell number,
a decrease in their apoptotic response, a rescue of their cell cycle progression, and
restoration of their Ki67 potential. BMAd release a high volume of FABP4, and exposure
to BMAd CM elicits an increase in internal FABP4 in MMlS cells, supporting recent
findings (Shu, 2020). Additionally, we observed that the fatty acid binding protein family
is important to MM cell growth using 3 cell lines that represent different type of MM
harboring different genetic abnormalities (RPMI8226, MMIS and OPM2 cell lines).
Basally, single inhibitors of FABP4 and 5 significantly impaired cell growth over time,
and this is consistent even in the presence of tumor-supportive BMAd CM. In addition,
when the single inhibitors were used in combination with dexamethasone, there was a
significant decrease in cell number and significantly increased apoptosis compared to
dexamethasone treatment alone in basal conditions. Importantly, combination treatment
of BMS, SBFI and dexamethasone resulted in the greatest reduction in cell number and
significantly higher apoptosis compared to any other treatment, resulting in an almost 7-
fold increase compared to the control in basal conditions. While FABP inhibition did not
reverse drug resistance in BMAd CM, combining the duel inhibitors resulted in a
significant increase in apoptosis and significant reduction in cell number. In summary,
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these data suggest that duel inhibition of BMS and SBFI does not resensitize MM cells to
dexamethasone in BMAd CM, and supports previous studies that additional adipokines
are likely involved in BMAd-induced drug resistance (H. Liu et a1.,2019;Z.Liu et al.,
2015). A need for future studies in myeloma dexamethasone drug resistance are needed
to elucidate other molecules in BMAd CM alleviating MM cells from dexamethasone-
induced apoptosis (M. L. Farrell & Reagan, 2018).
Overall, targeting the FABP family appears to be a promising new target in myeloma,
which could prove to be relevant in essentially all other forms of cancer. While targeting
FABPs does not reverse dexamethasone resistance, targeting FABP5 looks to be
clinically and translationally promising in multiple myeloma. FABP3, FABP4, FABP5,
and FABP6 are expressed in three common myeloma lines, with FABP5 being the
highest expressed. Clinically, high FABP5 expression correlates with poor outcomes and
is significantly higher in relapsed patients. Targeting the family of FABPs with the
pharmacological pan inhibitors, SBFI-26 and 8MS309403, impaired myeloma growth
and induced a level of apoptosis in vitro.Inhibition of FABPs in vivo significantly
reduced tumor burden and extended the life span of mice. While our dexamethasone-
SBFI tn vivo experiment did not demonstrate synergy, it is possible that higher doses than
we used herein could have better effects. Our data suggest that targeting FABPs could be
a beneficial and important avenue to treat myeloma or other cancer patients (M. Farrell,
Fairfield, D'Amico, Murphy, & Reagan, 2020).
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In future studies, we plan to broaden the scope of combination treatments to extend to
other anti-myeloma therapies both in terms of drug resistance and combination of FABP
inhibitors. We would plan to interrogate the in vitro effects of BMAds and FABPs on
MM resistance to proteasome inhibitors and/or immunomodulatory imide drugs, and
determine the mechanisms driving this type of resistance. In vivo, we plan to use mouse
models that have high BMAT either due to irradiation or diet, and test if MM cells are
resistant to other agents beyond dexamethasone. This year, I also published as first author
a manuscript showing that BM adiposity is reduced with anti-sclerostin antibody
treatment, suggesting that anti-sclerostin antibody could be used in combination with
dexamethasone to elucidate if MM cells respond better to dexamethasone when the
microenvironment is depleted of BMAd (M. Fanell, Fairfield, Costa, eta1.,2020).We
are also interested in using a commonly used antibiotic, Levofloxacin, to treat myeloma
burdened mice to reduce tumor growth. Levofloxacin has been showed to inhibit FABP4
activity and is currently used in the clinic for treatments in other cancers (Mukherjee et
a1.,2020).
Myeloma is currently incurable and the median survival is only five years, highlighting
that novel new treatments are needed to expand the quality and duration of life. Our data
illuminate that FABP5 is a novel therapeutic target and our findings demand more
investigation into its role in myeloma due to its potential of curing, or increasing life
expectancy for patients with this deadly disease.
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Supplemental Figure 1. FABP gene and protein expression levels are
influenced by BMAd CM. A, B) FABP4 protein levels are higher in BMAd CM
and in MM after BMAd CM treatment, as determined by ELISA. C) MM1S mRNA
































































Supplemental Figure 2. Exogenously added recombinant FABP4 or 5 protein
does not influence cell number. A, B) Exogenously added recombinant FABP4 or 5
protein did not influence MMlS cell number. C, D) Exogenously added recombinant






























Supplemental Table 1. FABP5 is the highest expressed FABP in OPM2,
RPMI8226 and MMIS cells. A) Basal expression levels of FABPs in OPM2,
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Supplemental Table 2. Combinatorial treatment of dexamethasone, BMS and
SBFI induce apoptosis and reduce cell number after 72 hour treatment in MMIS
cells. A-D) Statistical importance of treatment with 50 pM BMS, 50 pM SBFI, 80 ¡rM
dex and the combinations after 72 hours in MM1S cells.
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Supplemental Figure 4. SBFI, dexamethasone, or the combination treated mice
maintain weight. A) No weight difference between treatment groups over the
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